INTRODUCTION
Many efforts have been devoted to investigations of expansion and maintenance of functional hematopoietic stem cells (HSCs) for therapeutic purposes 1,2 . However, to date, none of the developed methods has been firmly demonstrated to be clinically valuable. Thus, deeper understanding of the mechanisms by which HSCs are generated, amplified and maintained in developing embryos may guide the future development of more effective techniques for therapeutic manipulations of HSCs.
The process of embryonic hematopoiesis can be separated into two stages: primitive and definitive hematopoiesis. Definitive hematopoiesis is characterized by the generation of adult-type HSCs in midgestation mouse embryos. HSCs form in the aorta-gonad-mesonephros (AGM) region at embryonic day 10.5 (E10.5) and subsequently migrate into the fetal liver at E11.5 3,4 . At E15.5, these HSCs are released into the circulating blood and begin to home to the bone marrow 5 . Of note, the number of HSCs increases drastically from 2-3 to 800-1000 in mouse fetal liver 4 , suggesting a unique and powerful effect of the fetal liver microenvironment on the expansion of HSCs. Therefore, identifying novel regulators and microenvironment cues for HSC development in fetal liver is of great importance.
In mouse fetal liver, stromal cells, hepatoblasts and endothelial cells are the three main cell types that significantly contribute to the extrinsic regulation of HSC development 6 . Among them, stromal cells harvested from either primary culture or immortalized cell lines express both mesenchymal (such as vimentin, osteopontin and alpha smooth muscle actin) and epithelial markers (such as alpha-fetoprotein, cytokeratins 8 and albumin), and are able to support hematopoiesis 7 . In addition, the stem cell factor (SCF) + DLK + hepatoblasts maintain the activity of HSCs by producing cytokines such as thrombopoietin (TPO), SCF, angiopoietin-like protein 3 (Angptl3) and insulin-like growth factor 2 (IGF2) 8 . Moreover, endothelial cells secrete the chemokine CXCL12 to promote HSC maintenance 9 . However, the core regulatory mechanism, particularly the transcriptional program that is operated in mosaic niche
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ATF4 is a basic-region leucine zipper (bZIP) transcription factor that is widely expressed in many tissues and cells, and functions as a stress response factor and a developmental regulator 10 . The absence of ATF4 induces partial perinatal lethality 11 , and results in severe anemia and abnormal erythropoiesis in E15.5 embryos 12, 13 .
However, whether ATF4 plays a critical role in definitive hematopoiesis at the stem cell level, such as de novo generation, migration, amplification and maintenance of HSCs, is therefore a logical and important question to be answered.
In this study, we show that ATF4 deletion does not affect initial HSC generation in the AGM region, but markedly impairs the expansion of functional HSCs in the fetal liver.
Mechanistically, ATF4 can transcriptionally up-regulate expression of Angptl3 in the niche cells, which may guarantee expansion and maintenance of functional HSCs during the unique wave of fetal liver hematopoiesis. 
Embryo dissection and single cell isolation
Embryonic developmental time was estimated by considering the day of vaginal plug observation as embryonic day 0.
(E0.5). Embryos between somite stages (S) 42S
and 48S (E11.5) were determined by somite counting. Dissections of the fetal liver (FL) and the AGM region were performed as previously described 15, 16 .
Flow cytometry
Fetal liver cells were incubated in various antibodies for 30 minutes in the dark at 4°C.
Stained cells were analyzed via fluorescence-activated cell sorting (FACS) using a FACS Calibur flow cytometer or were sorted using a FACS Aria II flow cytometer (BD Biosciences).
Competitive bone marrow transplantation (cBMT)
The cBMT experiments were performed as previously described
17
. More details can be found in supplemental methods.
Accession number
The microarray and RNA-seq data are available in the Gene Expression Omnibus database under the accession number GSE66382.
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Statistical analysis
The significance of differences were assessed using Student's t test; *P<0.05; **P<0.01; ***P<0.001. The data are presented as the means ± SEM. Ns: not significant. Additional experimental procedures are described in the supplemental Methods. Figure 1A ). Based on the chimerism, we calculated the repopulating units (RUs) 17, 18 . Assuming 10 5 BMNCs as one RU, we found a 10.8-fold reduction in the ATF4 -/-group ( Figure 1B) . However, the lineage differentiation spectrum of the ATF4 -/-donor cells was not significantly affected in peripheral blood and bone marrow of recipients (supplemental Figure 1A -B).
Because HSCs undergo drastic expansion in normal mouse fetal liver around E12.5 4 ,
we asked whether ATF4 deficiency negatively impact hematopoiesis at this time point.
As shown in Figure 1C- . There was around 1.8-fold reduction in repopulating potential of each HSC from E12.5 ATF4 -/-fetal liver (supplemental Table   1 ), suggesting a decreased yield of hematopoietic progenitor cells (HPCs).
Consistently, the CFC assay demonstrated that the size of ATF4 -/-colonies was markedly decreased (supplemental Figure 2A) Figure 2B ), indicating that ATF4 deletion could also significantly perturb the function of early HPCs in the E12.5 fetal liver.
Therefore, in addition to HPCs, development of HSCs was severely impaired in the ATF4 -/-fetal liver, as witnessed by 7.4-10.8 folds of reduction in RU from E12.5 to E15.5. This was largely due to the paucity of functional HSCs (4.2-fold reduction in CRU at E12.5) and also caused by compromised repopulation per HSC (1.8-fold reduction in MAS).
ATF4 deletion did not affect HSC generation in the AGM region.
The AGM region is considered as the predominant site of the de novo generation of HSCs in mice. Then we determined whether the HSC defect in ATF4 -/-fetal liver was caused by insufficient generation of HSCs in the AGM region. At E11.5, ATF4 -/-AGM region contained slightly fewer cells than ATF4 +/+ one ( Figure 2A ). Despite of this fact, when we injected single cell suspensions consisting of 1 ee of the AGM region to each recipient, we found that the mean chimerism was not significantly different between the two groups (WT: 55.8+6.4%, n=20; KO: 48.4+8.6%, n=21; 6 independent experiments) ( Figure 2B ). In addition, the ATF4 -/-donor cells could differentiate into These data demonstrated that the hematopoietic ability of E11.5 AGM region was not influenced by ATF4 deletion, suggesting that ATF4 deficiency did not affect the formation of the first population of HSCs prior to their colonization in the fetal liver. The slightly lower cellularity in ATF4 -/-AGM region might be attributed to the non-hematopoietic cells. Therefore, the decreased number and reduced function of HSCs in the fetal liver in the absence of ATF4 were unlikely due to a change in HSC genesis from the AGM region.
HSC migration was moderately suppressed in the absence of ATF4.
Upon emergence of HSCs in the AGM region, they migrate into circulating blood and colonize the fetal liver. Because the functional defect of HSCs generated in the AGM region was not observed, we then asked whether ATF4 deletion might negatively regulate the entry of HSCs into fetal liver. To this end, we analyzed the fetal liver at E11.5, the earliest time point when HSCs begin to reside and can be detected 4 . The Figure 3D ).
Taken together, to a certain extent, the moderate reduction in HSC migration might 9, 20, 21 . At the three time points analyzed, the HSC frequencies were all slightly increased ( Figure 4A -B, supplemental Figure   4A -D), but the numbers were reduced by around 1.5-fold in the ATF4 -/-group ( Figure   4C , supplemental Figure 4E -F).
In this study, we relied more on the functional assessment than phenotypic quantitation of HSCs. Therefore, we sorted the immunophenotypically-defined HSC population in the E14.5 ATF4 -/-fetal liver using the "SLAM" markers for mouse Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the differentially expressed genes revealed the enrichment of ten pathways, three of which were related to molecules in the fetal liver microenvironment: cell adhesion molecules (CAMs) (p-value=4.96e-13), cytokine-cytokine receptor interaction (p-value=9.94e-10) and extracellular matrix (ECM) receptor interaction (p-value=3.38e-6) (supplemental Table 2 ). Therefore, these data promoted us to focus more on the microenvironmental effects on HSCs in fetal liver. 7.7+1.6% vs. WT: 3.6+0.8%) (Supplemental Figure 8D -I). To determine the HSC-supporting ability of the two different cell subsets, we performed the assay by co-culturing wild-type ATF4 +/+ SLAM cells with these cells, respectively ( Figure 5A -B).
After 3-4 days, the cell number was similar, but the LSK frequency was higher in the ATF4 +/+ co-culture than ATF4 -/-counterpart ( Figure 5C -F). Subsequently, we transplanted these cultured cells into lethally-irradiated recipients (CD45.1). At 16
weeks after transplantation, we found that the chimera ratio was significantly decreased in ATF4 -/-endothelial cell co-culture (30.3+3.6%) compared to the ATF4 +/+ control (61.0+8.4%) ( Figure 5G ). A similar result was found in the stromal cell co-culture (KO: 7.8+2.4%; WT: 20.8+4.7%) ( Figure 5H ). Thus, the HSC-supporting ability of the ATF4 -/-fetal liver microenvironment was significantly reduced.
RNA-seq of ATF4 -/-stromal cells showed decreased expression of Angptl3 and

VEGFA.
To further elucidate the molecular basis by which the supporting ability of these stromal cells was defective, RNA-seq was performed on these cells harvested from 5 independent experiments, and the gene ontology (GO) terms of the gene set were analyzed using an established cytoscape plug-in: Enrichment Map
22
. The down-regulated genes were functionally enriched in four main biological processes:
lipid process, inflammatory response, response to stimulus, and coagulation ( Figure   6A ).
Some of the down-regulated genes such as Angptl3, VEGFA and IGF2 were previously demonstrated to be involved in hematopoiesis 1, 23, 24 . Thus, the expression of these genes and some other known hematopoietic cytokines (SCF, TPO, IGFBP2, CXCL12 and other Angptl family members) in fetal liver hematopoiesis was verified by real-time PCR [25] [26] [27] . Notably, the expression levels of Angptl3 and VEGFA were significantly decreased by 68% and 38% respectively in the ATF4 -/-group ( Figure 6B ), implying a role of ATF4 in the transcriptional regulation of these cytokines.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Angptl3 has been reported to support the activity of HSCs in bone marrow and fetal liver, and to be expressed by HSC-supportive fetal hepatoblasts 8, 27, 28 . As shown in Figure 6C , the protein levels of Angptl3 in the ATF4 -/-fetal liver homogenates were decreased. To determine the cellular source of Angptl3, we isolated hematopoietic , we analyzed them in the fetal liver. Interestingly, we found that hepatoblasts mainly existed in the
-stromal cell population, and their frequencies were similar between the two genotypes (supplemental Figure 9A ). Real-time PCR analysis
showed that the expression of Angptl3 mRNA was decreased in the ATF4 -/-DLK + SCF + hepatoblasts, similar to that in stromal cells ( Figure 6E ). Therefore, we suspected the ATF4 -/-hepatoblasts should be an important source of Angptl3 that was responsible for impaired function of HSCs in the aberrant fetal liver microenvironment.
Angptl3, but not VEGFA, partially rescued the defects of ATF4 -/-HSCs.
To further examine whether Angptl3 protein enhances the function of HSCs in the absence of ATF4, SLAM cells were sorted from the ATF4 -/-fetal liver and cultured with SCF, FLT3L and TPO in the presence or absence of Angptl3. After 4 days in culture, although the total cell numbers were similar, the frequencies of LSK cells (20.2+2.5%
vs. 18.5+2.9%) and CD48 -LSK cells (12.1+0.7% vs. 9.4+0.8%) were higher in the Angptl3-treated group than in the Angptl3-lacking group ( Figure 7A -B). Then we separately collected all of the cultured cells and injected these cells into lethally irradiated recipients (9 recipients per group from 3 independent experiments). At 16 weeks after transplantation, we found that the reconstitution ratio (chimerism>10%)
1 5 was higher in the Angptl3-treated group than in the control group (6/9 vs. 3/9) ( Figure   7C ). In contrast, no significant differences in the LSK frequency after 4 days co-culture or in the reconstitution ability at 16 weeks after transplantation were observed between the VEGFA-treated and VEGFA-lacking group (supplemental Figure 10A -B),
suggesting that VEGFA could not rescue the defective function of the ATF4 -/-HSCs.
In light of a previous study showing that the expression of Angptl is regulated by activating transcription factor (ATF) family members 30,31 , we next examined whether ATF4 exerts this effect on Angptl3. We first performed a ChIP assay and found that ATF4 directly binds to the Angptl3 promoter ( Figure 7D ). Next, we silenced ATF4 expression in the NIH 3T3 cell line using ATF4 siRNA, and the real-time PCR results
showed that the mRNA levels of Angptl3 were decreased due to treatment with ATF4 siRNA compared to control siRNA ( Figure 7E ). Furthermore, we performed western blot, and found the protein level of Angptl3 was also reduced by ATF4 siRNA ( Figure   7F ). Consistently, the over-expression of ATF4 cDNA elevated the expression of Angptl3 mRNA ( Figure 7G ). Taken together, our results suggested that ATF4 may play a direct role in the transcriptional regulation of Angptl3 in fetal liver cells.
DISCUSSION
It is well known that the fetal liver serves as an important and unique site for rapid amplification of functional HSCs during development but its underlying mechanism has been poorly understood. In this study, we found that ATF4 is a potent positive regulator for the functional expansion and repopulating efficiency of HSCs in mouse developing fetal liver. In contrast, it does not appear to significantly affect HSC genesis in AGM region and exerts a moderate effect on HSC entry into fetal liver.
In adult bone marrow, the HSC niche contains the osteoblast-abundant endosteal region in junction with the nearby endothelial vascular region 32 . ATF4 has been shown to promote osteoblastic development 33 as well as vascularization in bone marrow 14 .
Thus, because these known niche components are altered in the absence of ATF4, ATF4 is likely required for maintaining HSC-supportive niche throughout ontogeny and adulthood, despite presumably differed molecular circuits. In our current study, the expression of some cytokines, including Angptl3, VEGFA and IGF2, which are known to be involved in HSC development or regulation, was decreased in ATF4 Notably, given our data showing no significant changes in apoptosis, cell cycle or senescence of the HSCs in the absence of ATF4 (supplemental Figure 11A-F) , one possibility would be that, in the absence of ATF4, the mutant HSCs disfavor symmetric self-renewing division during the amplification of HSCs in fetal liver due to both intrinsic and extrinsic defects. In addition, our microarray data also found that Runx1t1 (Runt-related transcription factor 1; translocated to, 1) was significantly decreased in ATF4 -/-LSK cells. In addition to its classical essential role in definitive hematopoiesis, Runx1t1 was recently shown to be in a cocktail of several transcription factors, which was able to reprogram murine HPCs into functional HSCs
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. In addition, the unfolded protein response (UPR) has been recently shown to determine the integrity of HSC pool during endoplasmic reticulum (ER) stress, during which the expression of ATF4 in HSCs was higher than that in HPCs 36 . Therefore, whether ATF4 might regulate the HSC pool partially via UPR is of interest in our future investigation. These intriguing possibilities all deserve further investigations in the future.
Migration is critical for the dynamic development of HSCs in mouse embryos. 
